XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisition of Pelican Therapeutics - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2016
May 31, 2016
Jun. 30, 2020
Jun. 30, 2019
Mar. 31, 2018
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisition of Pelican Therapeutics                      
Discount rate           8.87%          
Accrued liabilities     $ 1,202,705     $ 1,202,705   $ 1,676,467      
Revenue     593,165 $ 342,487   1,495,045 $ 1,043,549        
Net loss (income)     (4,454,430) (4,770,870)   (10,746,536) (10,486,346)        
Net loss     $ 4,536,818 $ 4,944,905   $ 10,910,238 $ 10,763,986        
Pelican Therapeutics, Inc.                      
Acquisition of Pelican Therapeutics                      
Ownership interest in subsidiary     85.00%     85.00%   85.00%      
Pelican Therapeutics, Inc.                      
Acquisition of Pelican Therapeutics                      
Percentage of voting interests acquired in acquisition                 85.00% 80.00% 80.00%
Discount rate         8.87%            
Cash consideration         $ 200,000            
Percentage of non-controlling interest acquired     20.00%     20.00%          
Amount awarded from CPRIT grant   $ 15,200,000                  
Pelican Therapeutics, Inc. | Maximum                      
Acquisition of Pelican Therapeutics                      
Amount awarded from CPRIT grant $ 15,200,000                    
Pelican Therapeutics, Inc. | Stockholders                      
Acquisition of Pelican Therapeutics                      
Cash consideration         $ 300,000            
Pelican Therapeutics, Inc. | CEO                      
Acquisition of Pelican Therapeutics                      
Percentage of milestone payments that will be paid to related parties         20.40%            
Pelican Therapeutics, Inc. | Edward B. Smith                      
Acquisition of Pelican Therapeutics                      
Percentage of milestone payments that will be paid to related parties         2.00%            
Pelican Therapeutics, Inc. | John Monahan                      
Acquisition of Pelican Therapeutics                      
Percentage of milestone payments that will be paid to related parties         0.30%